CESARETTI, Marina
 Distribuzione geografica
Continente #
NA - Nord America 1.449
EU - Europa 916
AS - Asia 139
AF - Africa 2
OC - Oceania 2
SA - Sud America 1
Totale 2.509
Nazione #
US - Stati Uniti d'America 1.441
GB - Regno Unito 630
DE - Germania 82
SE - Svezia 66
CN - Cina 60
IT - Italia 40
UA - Ucraina 30
HK - Hong Kong 26
SG - Singapore 24
FI - Finlandia 22
TR - Turchia 20
FR - Francia 17
BG - Bulgaria 13
RU - Federazione Russa 6
BZ - Belize 4
CA - Canada 3
CZ - Repubblica Ceca 3
AU - Australia 2
ES - Italia 2
ID - Indonesia 2
IN - India 2
MY - Malesia 2
AT - Austria 1
BE - Belgio 1
CH - Svizzera 1
CR - Costa Rica 1
DZ - Algeria 1
EC - Ecuador 1
IE - Irlanda 1
KR - Corea 1
LK - Sri Lanka 1
MK - Macedonia 1
NG - Nigeria 1
TW - Taiwan 1
Totale 2.509
Città #
Southend 602
Fairfield 261
Ashburn 140
Woodbridge 140
Chandler 115
Houston 102
Cambridge 83
Wilmington 75
Seattle 70
Jacksonville 67
Dearborn 58
Nyköping 50
Ann Arbor 44
Frankfurt am Main 38
San Diego 27
Hong Kong 26
Beijing 21
New York 21
Modena 20
Izmir 17
Princeton 15
Bremen 13
Singapore 13
Sofia 13
Eugene 12
Helsinki 12
Shanghai 11
Milan 8
Falls Church 7
Redwood City 7
Boardman 5
Kilburn 5
London 5
Norwalk 5
Belize City 4
Chiswick 4
Saint Petersburg 4
San Jose 4
Brno 3
Phoenix 3
San Francisco 3
Segrate 3
Tappahannock 3
Toronto 3
Hounslow 2
Indiana 2
Jakarta 2
Madrid 2
Munich 2
Nanjing 2
Putian 2
Saint Louis 2
San Mateo 2
Washington 2
Albuquerque 1
Atlanta 1
Augusta 1
Bologna 1
Brussels 1
Castello 1
Collegeville 1
Colombo 1
Dallas 1
Dongguan 1
Dublin 1
Duncan 1
Florence 1
Guangzhou 1
Hangzhou 1
Jinan 1
Kuala Lumpur 1
Las Vegas 1
Leawood 1
Manchester 1
Mantova 1
New Taipei 1
Pavullo Nel Frignano 1
Port Harcourt 1
Prescot 1
Prilep 1
Quito 1
Redmond 1
San José 1
Shenyang 1
Shenzhen 1
Simi Valley 1
Sydney 1
Tianjin 1
Wandsworth 1
Yiwu 1
Totale 2.198
Nome #
Epidemiological overview of Hodgkin lymphoma across the Mediterranean Basin 638
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 241
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 206
Dismal outcome of t-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry 181
Use of 2-(18F)fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy 173
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study 165
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study 163
Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. 154
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pilori interventions: results from a population-based study on extranodal marginal zone lymphomas 151
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study 151
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 131
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma 124
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas 79
Totale 2.557
Categoria #
all - tutte 9.806
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.806


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020656 53 35 27 60 59 100 94 62 60 36 39 31
2020/2021567 55 21 50 70 52 36 40 56 45 69 44 29
2021/2022305 23 38 44 17 6 17 16 15 25 20 61 23
2022/2023287 30 39 15 33 37 44 2 29 44 1 5 8
2023/2024221 2 7 17 25 73 26 25 19 1 2 5 19
2024/202523 23 0 0 0 0 0 0 0 0 0 0 0
Totale 2.557